FdaApplication
NDA 020753
Identifiers
- fda_app_no: NDA020753
Properties
| Property | Value |
|---|---|
| applicant_name | PFIZER INC |
| application_type | NDA |
| approval_date | 1999-10-21 |
Revenue by product
AROMASIN
| Period | Revenue |
|---|---|
| Q3 2025 | $114.0M |
| Q2 2025 | $111.0M |
| Q1 2025 | $108.0M |
| Q3 2024 | $87.0M |
| Q2 2024 | $87.0M |
| Q1 2024 | $82.0M |
| Q4 2023 | $76.0M |
| Q3 2023 | $76.0M |
| Q2 2023 | $72.0M |
| Q1 2023 | $77.0M |
| Q4 2022 | $61.0M |
| Q3 2022 | $66.0M |
| Q2 2022 | $59.0M |
| Q1 2022 | $62.0M |
| Q4 2021 | $52.0M |
| Q3 2021 | $56.0M |
| Q2 2021 | $51.0M |
| Q1 2021 | $52.0M |
| Q4 2020 | $41.0M |
| Q3 2020 | $35.0M |
| Q2 2020 | $39.0M |
| Q1 2020 | $34.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| AROMASIN | EXEMESTANE | 25MG | TABLET;ORAL |
1 product